A Study to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial. Anticipate approximately 70 patients enrolled from start in this trial and approximately 70 patients to roll-over from trial NCT04076462.